Nurtec® ODT
(rimegepant)
orally disintegrating tablets 75 mg

Register today for an exciting live event that explores how Nurtec® ODT (rimegepant) is changing the migraine landscape by dissolving the line between acute and preventive treatment

Evolving Your Approach to Migraine With Nurtec ODT—the Only Dual Therapy for Acute and Preventive Treatment

Click the link below to register for the Biohaven product theater with migraine expert Dr Merle Diamond, at the 2021 Diamond Headache Update. The event will take place at Disney's Grand Floridian Resort & Spa in Lake Buena Vista, Florida.

SAVE THE DATE:

Saturday, July 17, 2021
6:30 AM ET
Disney's Grand Floridian Resort & Spa
Salons 6-9

Complimentary breakfast will be provided

MERLE DIAMOND, MD
President, Managing Director
Diamond Headache Clinic
Chicago, Illinois
Clinical Assistant Professor, Department of Medicine
Chicago Medical School at Rosalind Franklin University of Medicine and Science
Chicago, Illinois

REGISTER for the Diamond Headache Update 2021

CLICK HERE for the Diamond Headache Update 2021 Schedule of Events

INDICATION

Nurtec® ODT (rimegepant) is indicated in adults for the:
- acute treatment of migraine with or without aura
- preventive treatment of episodic migraine

IMPORTANT SAFETY INFORMATION

Contraindications: Hypersensitivity to Nurtec ODT or any of its components.

Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash, and can occur days after administration.

Adverse Reactions: The most common adverse reactions were nausea (2.7% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo) and abdominal pain/dyspepsia (2.4% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with Nurtec ODT.

Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4, strong or moderate inducers of CYP3A or inhibitors of P-gp or BCRP. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4.

Use in Specific Populations: *Pregnant/breast feeding*: It is not known if Nurtec ODT can harm an unborn baby or if it passes into breast milk. *Hepatic impairment*: Avoid use of Nurtec ODT in persons with severe hepatic impairment. *Renal impairment*: Avoid use in patients with end-stage renal disease.

Please see accompanying full Prescribing Information.

The content of this product theater and the views expressed are those of Biohaven Pharmaceuticals, and not those of the Diamond Headache Update. Inclusion of links to this content should not be construed as an endorsement.

US-RIMODT-2100508. 06/30/2021.

biohaven pharmaceuticals